Developing Therapeutics That Teach the Body to Heal Itself
NEWS RELEASES
Search all of our news releases here.
Immunotherapy CEO Jeff Galvin Joins The Board of Directors of the Cancer Support Community
ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ — Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC)…. [Read More]
American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs
ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors… [Read More]
American Gene Technologies CEO Jeff Galvin Joins Maryland Tech Council Board of Directors
ROCKVILLE, MD, UNITED STATES, August 20, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT)’s CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council, the largest Maryland technology trade association, representing over 600 companies across the… [Read More]
American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention
ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as… [Read More]
American Gene Technologies Gains Additional Immuno-Oncology Patent
Novel approach to activating gamma delta T cells shows promise in animal studies — demonstrating efficacy in multiple epithelial solid tumors and metastases ROCKVILLE, Md., March 19, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced… [Read More]
American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure
Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 – American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes… [Read More]
American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells
Patent encompasses AGT’s advanced gene and cell therapy strategy for oncology ROCKVILLE, MD, December 12, 2017 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced the issuance of U.S. Patent No: 9,834,790 dated December 5, 2017, covering methods of… [Read More]
AGT CSO, David Pauza, to Present HIV cure data At The Cell & Gene Meeting on the Mesa
ROCKVILLE, MD., September. 26, 2017 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a gene technology company focusing on a lentiviral delivery platform, today announced that Chief Science Officer C. David Pauza, Ph.D., will present at the upcoming Cell & Gene Meeting on the Mesa… [Read More]
AGT Builds Montgomery County Gene & Cell Therapy Momentum
Fast Growing Maryland Biotech Company Moves to a 24,000 Sq. Ft. Location and Will Host Ribbon Cutting Ceremony on October 23, 2017. September 25, 2017. Montgomery County, MD: American Gene Technologies (AGT), a private Maryland biotechnology company developing cures and treatments for Infectious diseases, cancers and monogenic disorders,… [Read More]
American Gene Technologies Inc. Appoints Julia R. Brown to its Board of Directors
ROCKVILLE, Md., Sept. 11, 2017 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company with a broad and robust lentiviral drug-development platform, today announced the appointment of Julia R. Brown to its board of directors. Jeffrey A. Galvin… [Read More]
Subscribe to News Releases and News Updates
Subscribe to our news release and published article updates to be notified when we release new content!
